Related Experiment Video
Updated: May 23, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura
N Child1, M O'Carroll, L Berkahn
1Department of Haematology, Auckland Hospital, Auckland City Hospital, Auckland, New Zealand. nchild@adhb.govt.nz
Abstract:
We report the case of an 84-year-old man with refractory immune thrombocytopenia purpura (ITP) who was treated with rituximab and subsequently developed severe interstitial lung disease. There has been increasing use of rituximab in the treatment of ITP with success rates of up to 62% in adult patients with recurrent ITP. Interstitial lung disease is a rare but recognised complication of rituximab but has been rarely reported in the setting of ITP.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Rheumatic Heart Disease I: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents